|Day Low/High||31.60 / 32.30|
|52 Wk Low/High||23.12 / 36.09|
The Wall Street Journal reported a 'pattern of sexual misconduct' by the billionaire casino mogul.
Jim Cramer is bullish on CVS Health, Intuitive Surgical, Allergan, Paycom Software, Huntsman.
Reports of the death of Facebook, Apple, Amazon, Netflix, Nvidia and Google/Alphabet are greatly exaggerated, says Jim Cramer.
Clariant boss says White Tale demands are either "tactical or for its own benefit" but concedes it could look at deals to make specialty chemcials group more profitable.
Investors shrugged off concerns over corporate tax cuts and investigations into the Trump administration amid a busy slate for earnings and economic data
The Swiss company was forced to abandon its merger with Huntsman last week after it came under pressure from activist fund White Tale, which said the merger undervalued Clariant.
U.S. stock futures are rising on Friday, and the tech-heavy Nasdaq index is poised for sharp opening gains after Amazon.com, Alphabet, Microsoft and Intel issue powerful earnings reports.
The ECB's super dovish message was good for the markets.
Activist hedge fund White Tale Holdings may have a big enough stake to block Clariant's $20 billion merger with Huntsman Corp.
The Swiss chemicals group and its U.S. rival said Friday that they had agreed to call off their planned $20 billion merger by mutual agreement amid pressure from activist investor White Tale
This market is unique in the way fresh leadership emerges each day to take it higher, Jim Cramer says.
U.S. stock futures point to a higher opening for Wall Street on Tuesday, as the Federal Reserve begins its two-day policy meeting.
Activist investor Keith Mesiter continues to turn the screws on Swiss chemicals group Clariant AG
Vantiv could have opted to move its headquarters to the United Kingdom in the wake of its $10.4 billion purchase of Worldpay Group. Instead, it will stay put in Cincinnati.
Activist investment group White Tale Holdings is pressuring the company to merge with Huntsman.
Ilan Kaufthal arrives while Tronox's acquisition of Cristal's titanium dioxide assets is under FTC review.
U.S. stock futures are mixed on Wednesday in a return from the July 4 break.
Jim Cramer likes Xilinx and Abbott Labs, but he's bearish on Xerox and Huntsman.
Comey's testimony? U.K. elections? Eurozone news? These can be new buying opportunities, says Jim Cramer.
The Huntsman-Clariant deal has the makings of an inversion -- and it may be a sign of hopes the Trump administration will ease regulations on such cross-border deals.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.